(Q36417304)

14 August 2017

1 reference

title

Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis (English)

1 reference

14 August 2017

0 references

1

John P Bilezikian

1 reference

14 August 2017

2

Mishaela R Rubin

1 reference

14 August 2017

1 March 2006

1 reference

Current osteoporosis reports

14 August 2017

1 reference

14 August 2017

4

1 reference

14 August 2017

1

1 reference

14 August 2017

5-13

1 reference

https://scigraph.springernature.com/pub.10.1007/s11914-006-0009-2

14 August 2017

0 references

cites work

Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women

1 reference

12 December 2020

Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

1 reference

12 December 2020

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

12 December 2020

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

1 reference

12 December 2020

Hyperparathyroidism associated with sarcoma of bone

1 reference

12 December 2020

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Hyperparathyroidism with multiple malignant tumours of bone with giant-cells. A case report

1 reference

12 December 2020

Combination and sequential therapy for osteoporosis

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy

1 reference

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

12 December 2020

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

12 December 2020

Effects of Intermittent Parathyroid Hormone Administration on Bone Mineralization Density in Iliac Crest Biopsies from Patients with Osteoporosis: A Paired Study before and after Treatment

1 reference

12 December 2020

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

1 reference

12 December 2020

Daily and cyclic parathyroid hormone in women receiving alendronate

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

12 December 2020

Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans

1 reference

12 December 2020

Risk of new vertebral fracture in the year following a fracture

1 reference

12 December 2020

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

1 reference

12 December 2020

On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism

1 reference

12 December 2020

Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence

1 reference

12 December 2020

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

1 reference

12 December 2020

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

1 reference

12 December 2020

Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

1 reference

12 December 2020

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

12 December 2020

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

12 December 2020

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

1 reference

12 December 2020

Osteosarcoma of bone in apatient with primary hyperparathyroidism: a case report

1 reference

12 December 2020

Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

12 December 2020

Oral delivery of biologically active parathyroid hormone

1 reference

12 December 2020

Clinical practice. Postmenopausal osteoporosis

1 reference

12 December 2020

A comprehensive review of treatments for postmenopausal osteoporosis

1 reference

12 December 2020

Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study

1 reference

12 December 2020

Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma

1 reference

12 December 2020

Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Parathyroid hormone as an anabolic skeletal therapy

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures

1 reference

12 December 2020

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

1 reference

12 December 2020

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

1 reference

12 December 2020

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

1 reference

12 December 2020

Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment

1 reference

12 December 2020

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

1 reference

12 December 2020

10.1007/S11914-006-0009-2

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16527002